# Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

> **NCT04460560** · PHASE3 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 50 (actual)

## Conditions studied

- Hepatorenal Syndrome

## Interventions

- **DRUG:** Terlipressin

## Key facts

- **NCT ID:** NCT04460560
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-11
- **Primary completion:** 2023-12-27
- **Final completion:** 2023-12-27
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460560, "Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04460560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*